Moderna (NASDAQ:MRNA) Posts Earnings Results, Beats Expectations By $0.51 EPS

Moderna (NASDAQ:MRNAGet Rating) issued its quarterly earnings results on Wednesday. The company reported $5.24 EPS for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51, Briefing.com reports. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The firm had revenue of $4.73 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the previous year, the firm posted $6.46 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year.

Moderna Price Performance

NASDAQ MRNA traded down $7.34 during trading hours on Friday, reaching $186.84. The company’s stock had a trading volume of 5,426,044 shares, compared to its average volume of 4,710,197. The firm’s 50-day moving average price is $152.33 and its 200-day moving average price is $152.85. The company has a quick ratio of 1.56, a current ratio of 1.99 and a debt-to-equity ratio of 0.04. Moderna has a 1 year low of $115.61 and a 1 year high of $497.49. The company has a market capitalization of $74.32 billion, a price-to-earnings ratio of 5.69, a PEG ratio of 1.09 and a beta of 1.61.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MRNA shares. Piper Sandler decreased their price objective on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. SVB Leerink boosted their price objective on shares of Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday, August 1st. Finally, Morgan Stanley decreased their price objective on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $226.92.

Insider Buying and Selling

In related news, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $192.94, for a total value of $7,717,600.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at approximately $1,044,180,861.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 5,000 shares of Moderna stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $168.88, for a total value of $844,400.00. Following the sale, the president now owns 1,624,231 shares of the company’s stock, valued at approximately $274,300,131.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $192.94, for a total value of $7,717,600.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $1,044,180,861.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 606,029 shares of company stock valued at $91,997,025. Corporate insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several large investors have recently modified their holdings of the stock. Brighton Jones LLC increased its position in shares of Moderna by 5.8% during the 1st quarter. Brighton Jones LLC now owns 1,856 shares of the company’s stock valued at $320,000 after purchasing an additional 102 shares during the last quarter. Stonebridge Capital Advisors LLC boosted its holdings in Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after acquiring an additional 125 shares during the period. RB Capital Management LLC boosted its holdings in Moderna by 7.5% during the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock valued at $391,000 after acquiring an additional 158 shares during the period. SVB Wealth LLC boosted its holdings in Moderna by 12.3% during the 1st quarter. SVB Wealth LLC now owns 1,501 shares of the company’s stock valued at $258,000 after acquiring an additional 164 shares during the period. Finally, Parkside Financial Bank & Trust boosted its holdings in Moderna by 173.5% during the 1st quarter. Parkside Financial Bank & Trust now owns 309 shares of the company’s stock valued at $53,000 after acquiring an additional 196 shares during the period. Institutional investors own 61.20% of the company’s stock.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Earnings History for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.